Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of ART5803 in Healthy Participants
NCT06575153Phase 1Completed
- Sponsor
- Arialys Therapeutics
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ART5803 in Autoimmune Encephalitis (AE) (6 arms), sponsored by Arialys Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 12 weeks, Clinically significant changes in physical and neurological examination findings at 12 weeks and 7 more. Started Sep 2024; status: completed.
02
Drugs
ART5803
03
Conditions
Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT06575153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575153.